Abbott Laboratories (NYSE:ABT) shares came under pressure after the company on Thursday reported a sales miss for the fourth quarter and announced an "underwhelming" revenue guidance for 2026, according to BTIG.

• What’s next for ABT stock?

The Abbott Laboratories Analyst: Analyst Marie Thibault reiterated a Buy rating, while cutting the price target from $145 to $140.

The Abbott Laboratories Thesis: Nearly all segments of the company missed expectations in the fourth quarter and the Devices business "was not the bright spot it typically is," Thibault said in the note.

Abbott Laboratories indicated that the fourth-quarter miss was mainly due to the Nutrition segment due to disappointing consumer demand and a decline in volumes after price recent price hikes, she added.

Check out other analyst stock ratings.

For the first quarter, management guided to adjusted earnings of $1.12-$1.18 per share, the analyst stated. Abbott Laboratories guided to 2026 organic sales growth of 6.5%-7.5% and adjusted earnings of $5.55-$5.80 per share, which reflects 10% year-on-year growth at the midpoint, she further mentioned.

"The company is reducing its prices, using promotions, and will release new products this year, but 1H26 is expected to remain weak for Nutrition," Thibault wrote. She expects the company's organic sales growth to be light in the first half and accelerate in back half of the year, "assuming some recovery and return to growth in Nutrition."

ABT Price Action: Shares of Abbott Laboratories are up 0.29% to $108.92 at the time of publication on Friday.

Photo: Shutterstock